GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » Asset Turnover

BioLargo (BioLargo) Asset Turnover : 0.59 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is BioLargo Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BioLargo's Revenue for the three months ended in Dec. 2023 was $4.37 Mil. BioLargo's Total Assets for the quarter that ended in Dec. 2023 was $7.38 Mil. Therefore, BioLargo's Asset Turnover for the quarter that ended in Dec. 2023 was 0.59.

Asset Turnover is linked to ROE % through Du Pont Formula. BioLargo's annualized ROE % for the quarter that ended in Dec. 2023 was -41.92%. It is also linked to ROA % through Du Pont Formula. BioLargo's annualized ROA % for the quarter that ended in Dec. 2023 was -39.54%.


BioLargo Asset Turnover Historical Data

The historical data trend for BioLargo's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo Asset Turnover Chart

BioLargo Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.57 0.64 1.49 1.87

BioLargo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.65 0.22 0.40 0.59

Competitive Comparison of BioLargo's Asset Turnover

For the Chemicals subindustry, BioLargo's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLargo's Asset Turnover Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioLargo's Asset Turnover distribution charts can be found below:

* The bar in red indicates where BioLargo's Asset Turnover falls into.



BioLargo Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

BioLargo's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=12.23/( (4.858+8.205)/ 2 )
=12.23/6.5315
=1.87

BioLargo's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=4.37/( (6.545+8.205)/ 2 )
=4.37/7.375
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


BioLargo  (OTCPK:BLGO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

BioLargo's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.916/6.9565
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.916 / 17.48)*(17.48 / 7.375)*(7.375/ 6.9565)
=Net Margin %*Asset Turnover*Equity Multiplier
=-16.68 %*2.3702*1.0602
=ROA %*Equity Multiplier
=-39.54 %*1.0602
=-41.92 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

BioLargo's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-2.916/7.375
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2.916 / 17.48)*(17.48 / 7.375)
=Net Margin %*Asset Turnover
=-16.68 %*2.3702
=-39.54 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


BioLargo Asset Turnover Related Terms

Thank you for viewing the detailed overview of BioLargo's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLargo (BioLargo) Business Description

Traded in Other Exchanges
N/A
Address
14921 Chestnut Street, Westminster, CA, USA, 92683
BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.
Executives
Linda Park director 14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray director PO BOX 234, FREDERICK CO 80530
Jack B. Strommen director 7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii director 1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan director 30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert director, 10 percent owner, officer: Chief Executive Officer 3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc 10 percent owner 16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan officer: Chief Financial Officer 8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano director, officer: Corporate Secretary 3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc. 10 percent owner 2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code 10 percent owner 16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison director
Eduardo Ruiz director, 10 percent owner